Open in interactive viewer → charts, metric popovers & call review

Chicago Atlantic BDC Just Ran Out of Room to Grow — Right When It Finally Learned How

Record originations, $6.7 million of liquidity, a $500 million shelf that's live, and a merger that slipped to 2027
LIEN · Earnings Call · 2026-11-12

Chicago Atlantic BDC Just Ran Out of Room to Grow — Right When It Finally Learned How

For three quarters, LIEN's pitch has been that its niche is so underserved — no banks, no new private credit entrants in cannabis — that it can originate through any cycle. The third quarter of 2026 proved the origination half of that claim and quietly broke the other half. The company funded $72 million to two new borrowers, pushed the portfolio to a record $399.6 million, and lifted year-to-date gross originations to roughly $167 million, also a record. In the same quarter it nearly exhausted its revolver: $91 million drawn on a $100 million facility, leaving $6.7 million of total liquidity as of November 11.

The constraint arrives, politely

Interim CFO Tom Geoffroy described the situation without drama: “While we are approaching the capacity of our line of credit, we remain underlevered and are exploring opportunities for new sources of liquidity.” — Thomas Geoffroy, Interim Chief Financial Officer · 2026-11-12 That is the whole quarter in one sentence. The line of credit that funded the record origination activity is now the binding constraint, not credit quality and not borrower demand.

The tell is that this was forecast. On the May 2026 call, analyst Pablo Zuanic asked whether the company would make full use of the revolver by year end. Peter Sack's answer: “We would certainly aim to do so.” — Peter Sack, Chief Executive Officer · 2026-05-14 He did. Now the follow-up question — can you tap the $500 million shelf before the proposed merger closes? — gets a clean answer: “We do not need to wait for the merger to be completed to tap the shelf, secure additional debt capacity, and issue additional deployments.” — Peter Sack, Chief Executive Officer · 2026-11-12

We are ready to move quickly towards closing once approval is received, though we now expect the process to extend into 2027.

Peter Sack, Chief Executive Officer · 2026-11-12

That is the pivot of this report. A year ago the shelf was an abstraction — “It's too early to speak to what rates we may or may not be able to get and when we might raise the capital” — Peter Sack, Chief Executive Officer · 2026-05-14 — and the REFI merger was the scale answer to access to capital. Now the shelf is the only live tool, and the merger has slipped beyond its own guidance window. Management says Q1 2027 is "certainly possible" but refuses to commit, and Dino Colonna concedes that as the revolver fills, closings may slow in the fourth quarter. A company that has spent two years arguing its pipeline is the scarce asset is now signaling that capital is.

Two loans, 18% of the book, and no color

The deployment deserves more scrutiny than it got. $72 million across two borrowers, against an average debt investment of $9.4 million (2.4% of the portfolio at fair value), means this quarter's growth was roughly four times normal ticket size in two undisclosed private names. Zuanic pressed on Nirvana and STIIIZY. Colonna's answer: “We don't comment on specific transactions.” — Bernardino Colonna, President · 2026-11-12 Asked about the FLUENT loans now inside Vireo Growth, Sack deflected to another issuer's disclosures. Notably, the largest public MSOs — the borrowers with actual public paper trails — are explicitly not the target market.

The offsetting evidence is genuinely strong, and it is why this reads as a funding story rather than a credit story: 100% senior secured, no non-accruals versus an industry average of 3.7% of cost, 95% of the portfolio risk-rated 2 with 5% at 3 and nothing in the 4 or 5 buckets, one small migration from 2 to 3, and BDC sector-irrelevant software exposure of just 2.4%. A 15.5% weighted average yield against 10.7% for the average public BDC is a real spread for credit quality that has, so far, held.

The theme that quietly left the room

What management stopped emphasizing is as informative as what it added. The non cannabis diversification story ranked second in the company's own keyword set in Q1 2026 and ninth in Q2. This quarter it is effectively gone from the top of the list, replaced by core market language. Asked directly about the direct lending pipeline, Colonna offered enthusiasm without a number: activity is healthy versus the capital base. That is a softer answer than the 20%–30% portfolio target implies.

The cannabis catalyst language softened too. Adult use rescheduling has slowed, and the Schedule III medical move — ranked first among the company's keywords back in 2025Q3 — is now a background fact rather than a growth driver. Sack is explicit that federal policy is not in the model: “we do not incorporate potential regulatory changes in our projections, and we underwrite to the current regulatory framework.” — Peter Sack, Chief Executive Officer · 2026-11-12 And where the May call described a pipeline increasingly driven by M&A and said “The excitement is there” — Peter Sack, Chief Executive Officer · 2026-05-14, this quarter's version comes with a qualifier: “I think some of that's right with regards to some of the largest MSOs. However, our core market is not necessarily the largest public MSOs.” — Peter Sack, Chief Executive Officer · 2026-11-12

One cross-check on the merger's premise. REFI reported three days earlier, and its keyword set reads Mortgage REIT, commercial mortgage, investor community, principal balance. LIEN's reads senior secured, direct lending, adult use. The "complementary portfolios" claim is technically true — the two books share almost no vocabulary, no borrowers, and no cycle. That is diversification. It is not scale in origination, and the deal's stated benefit was scale.

A seven-turn multiple and a leverage ratio that is finally moving

The tape explains the urgency. LIEN is down 35.1% since February 2022 and 9.3% over the last 90 days, sitting 12.2% below its September 23 peak of $10.35, on a $206 million market cap. The stock changes hands at 7.0x net income, down 33% year over year and against 42.7x as recently as Q4 2024. Hence the open-market purchases of roughly 68,000 shares by management, and hence Peter Sack's citation of KBW data showing LIEN as the best-performing BDC in the $100–300 million band over the LTM at +3.2% total return versus −15.2% for the group. Relative outperformance inside an absolute drawdown is a strange thing to lead with, but it is the honest one.

The leverage story cuts both ways. A 0.3x debt-to-equity ratio against a 1.3x BDC average is real headroom, but the balance sheet is no longer static: liabilities to assets hit 12.1%, up 3.0 percentage points year over year from roughly 1% in 2022. The constraint on growth is the size of the facility, not the statutory limit — which is precisely why tapping the shelf matters more than the leverage statistic suggests. Financing at a discount to a $13.27 NAV, with a $0.34 dividend held for nine consecutive quarters and an 11% annualized NII return on book, transfers value between shareholders. That is the trade-off hiding behind "additional financial flexibility."

The one offensive asset in the pitch is duration. 65% of the debt portfolio is fixed-rate or sitting at its floor, and management now frames that as upside rather than insulation — a 100 basis point increase would benefit 78% of the book. That is a nicer story in a market fixated on Rising interest rate environments than the defensive framing of prior quarters, and it is a genuine differentiator against the alternative managers whose shares have de-rated alongside fee related earnings and fee-paying AUM over the past year. LIEN's problem is not that floating-rate credit has gone out of favor. It is that the cheapest dollar it has ever had access to is nearly spent, and the next one arrives on someone else's terms.